Eagle Pharmaceuticals,Inc. (TLV:TEVA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of President and Chief Commercial Officer; Resignation of Director; Resignation of President
On January 2, 2017, in connection with his appointment as President and Chief Commercial Officer of Eagle Pharmaceuticals, Inc., or the Company, David Pernock resigned from the board of directors of the Company, or the Board, (including his position as a member of the Board’s Nominating and Corporate Governance Committee). In addition, in connection with Mr. Pernock’s appointment, Scott Tarriff resigned from his position as President of the Company, effective January 2, 2017. Mr. Tarriff will continue to serve as the Company’s Chief Executive Officer and as a member of the Board.
A description of the terms of Mr. Pernock’s employment with the Company, as well as a copy of Mr. Pernock’s employment offer letter, were included in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 19, 2016.